Skip to main content
. 2019 Dec 20;23(3):510–519. doi: 10.1007/s10120-019-01034-7

Table 1.

Best overall response in the overall population

n (%) Overall population
Nivolumab (n = 268) Placebo (n = 131)
Best overall response
 CR 3 (1.1) 0
 PR 29 (10.8) 0
 SD 76 (28.4) 33 (25.2)
 PD 124 (46.3) 79 (60.3)
 NE 36 (13.4) 19 (14.5)
Objective response rate (CR or PR) 32 (11.9) 0
Disease control rate (CR, PR, or SD) 108 (40.3) 33 (25.2)

CR complete response, NE not evaluable, PD progressive disease, PR partial response, SD stable disease